Preparation of tumor-specific magnetoliposomes and their application for hyperthermia

被引:66
|
作者
Le, B
Shinkai, M
Kitade, T
Honda, H
Yoshida, J
Wakabayashi, T
Kobayashi, T [1 ]
机构
[1] Nagoya Univ, Grad Sch Engn, Dept Biotechnol, Nagoya, Aichi 4648603, Japan
[2] Nagoya Univ, Grad Sch Med, Dept Neurosurg, Nagoya, Aichi 4668550, Japan
关键词
hyperthermia therapy; magnetic particle; drug delivery; antibody; immobilization;
D O I
10.1252/jcej.34.66
中图分类号
TQ [化学工业];
学科分类号
0817 ;
摘要
Magnetoliposomes (MLs) were conjugated with an antibody fragment to give specificity to a tumor. The antibody fragment was cross-linked to N-(6-maleimidocaproyloxy)-dipalmitoyl phosphatidylethanolamine (EMC-DPPE) in tiposomal membrane. The immobilization of the antibody fragment was optimal when the content of EMC-DPPE was 10-wt% and the reaction time for immobilization was 18 h. The Fab' fragment-conjugating hits (FMLs) were 2.4 times higher molar immobilization density compared with the method using the whole antibody. The targetability of the FMLs to the glioma cells, U251-SP, was then investigated. The amount of FMLs uptake reached 85 pg/cell in an in vitro experiment using plastic dishes. In an in vivo experiment using glioma-harboring mice, 260 mug of the FMLs per 1 g of tumor tissue accumulated (tumor sizes was 0.1 cm(3)), which corresponded to approximately 60% of the total injection. This value was 7 times higher than that of the MLs. After injection of the FMLs, mice were exposed to intracellular hyperthermia using the alternating magnetic field irradiation. The temperature of tumor tissue increased to 43 degreesC and the growth of the tumor was found to be arrested over 2 weeks. These results indicate the FMLs could target the glioma cells in vitro and in vivo, and are efficiently applicable to the hyperthermia of tumor.
引用
收藏
页码:66 / 72
页数:7
相关论文
共 50 条
  • [11] Tumor-specific T-bodies: towards clinical application
    Eshhar, Z
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1997, 45 (3-4) : 131 - 136
  • [12] Tumor-specific T-bodies: towards clinical application
    Zelig Eshhar
    Cancer Immunology, Immunotherapy, 1997, 45 : 131 - 136
  • [13] MAGNETIC FLUID HYPERTHERMIA (MFH®): A NEW THERMOTHERAPY AGAINST CANCER WITH TUMOR-SPECIFIC NANO PARTICLES
    Charite, Andreas Jordan
    ANTICANCER RESEARCH, 2004, 24 (5D) : 3690 - 3690
  • [14] Dual stimulus of hyperthermia and intracellular redox environment triggered release of siRNA for tumor-specific therapy
    Yang, Yanfang
    Yang, Yang
    Xie, Xiangyang
    Xu, Xueqing
    Xia, Xuejun
    Wang, Hongliang
    Li, Lin
    Dong, Wujun
    Ma, Panpan
    Liu, Yuling
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2016, 506 (1-2) : 158 - 173
  • [15] ANTIBODY-CONJUGATED MAGNETOLIPOSOMES FOR TARGETING CANCER-CELLS AND THEIR APPLICATION IN HYPERTHERMIA
    SHINKAI, M
    SUZUKI, M
    IIJIMA, S
    KOBAYASHI, T
    BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, 1995, 21 : 125 - 137
  • [16] HUMAN TUMOR-SPECIFIC ANTIGENS
    HELLSTRO.I
    PIERCE, GE
    HELLSTRO.KE
    SURGERY, 1969, 65 (06) : 984 - &
  • [17] Tumor-specific immune responses
    Schreiber, Hans
    SEMINARS IN IMMUNOLOGY, 2008, 20 (05) : 265 - 266
  • [18] A tumor-specific stem cell
    Metcalfe, Ciara
    de Sauvage, Frederic J.
    NATURE GENETICS, 2013, 45 (01) : 7 - 9
  • [19] DISSECTION OF TUMOR-SPECIFIC ANTIGENICITY
    WORTZEL, RD
    STAUSS, HJ
    VANWAES, C
    SCHREIBER, H
    CANCER SURVEYS, 1985, 4 (01) : 115 - 134
  • [20] Tumor-specific apoptosis induction
    Leliveld, R
    PROTEIN MODULES IN CELLULAR SIGNALLING, 2001, 318 : 384 - 394